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Available online 21 June 2016AbstractObjective: The purpose of this study was to evaluate changes in bone quantity based on bone mineral density (BMD) and bone quality based on
trabecular bone score (TBS) in Graves' disease patients after anti-thyroid therapy.
Research design and method: This retrospective study included premenopausal female and male patients with Graves' disease who received
BMD measurement more than two times during treatment. BMD and thyroid function tests with free thyroxine (FT4), total triiodothyronine
(T3), thyroid stimulating hormone (TSH), and TSH receptor antibody (TRAb) levels were collected two times during follow-up. TBS was
calculated using TBS insight® software (version 2.1) from dual-energy X-ray absorptiometry images.
Results: Thirty Graves' disease patients (17 males, 56%; 13 premenopausal females, 44%) with a mean age of 35.3 ± 9.9 years were included.
The mean follow-up period was 20.7 ± 8.5 months. The median levels of FT4, TSH and TRAb improved at follow-up [2.55 ng/dL (Interquartile
range (IQR) 2.07e3.78) to 1.28 ng/dL (IQR 1.23e1.39), 0.015 mIU/L (IQR 0.01e0.04) to 0.89 mIU/L (IQR 0.35e1.55), 17.0 IU/L (IQR
5.0e40.3) to 5.0 IU/L (5.0e6.0), respectively; p < 0.001]. Median BMD (lumbar spine) values also improved from 1.118 g/cm2 (IQR
1.000e1.119) to 1.167 g/cm2 (IQR 1.050e1.219) ( p ¼ 0.001) at follow-up. TBS increased from 1.377 (IQR 1.299e1.422) to 1.390 (IQR
1.327e1.430) after treatment ( p ¼ 0.038).
Conclusion: Both bone quality and density improved after anti-thyroid treatment in premenopausal female and male Graves' disease patients.
© 2016 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Hyperthyroidism is a risk factor for osteoporosis due to
increased bone turnover rate stimulated by thyroid hormone
[1e3]. A meta-analysis found that BMD score decreases and
fracture risk increases in hyperthyroid patients [3]. Several
studies have shown that the increased fracture risk returns
almost to normal after treatment with anti-thyroid therapy* Corresponding author. Department of Endocrinology and Metabolism,
Ajou University School of Medicine, 164 World cup-ro, Suwon, Republic of
Korea.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).even without specific osteoporosis treatment, but not all
studies agree [3e5]. Most studies have focused on data from
bone densitometry (BMD) [1e3,5].
Bone strength associated with osteoporotic fracture is
determined by material formation and structural consider-
ations [6]. Although BMD measurement by dual-energy X-ray
absorptiometry (DXA) is an effective, non-invasive, and
quantitative method to assess fracture risk, it has a limited
ability to reflect bone structure. Trabecular bone score (TBS)
is a new texture parameter in DXA image analysis [7e10], and
so does not require any additional radiation exposure or time
by the patient. TBS measures gray level variations in DXA
images of the lumbar spine and incorporates them into a score
[8,10], allowing a reflection of bone quality by estimatinglsevier B.V. This is an open access article under the CC BY-NC-ND license
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of secondary osteoporosis associated with conditions like
diabetes and hyperparathyroidism have used TBS [11,12]. But,
to the best of our knowledge, no study has addressed bone
quality changes using TBS, and only a few studies using
BMD, in Graves' disease.
Therefore, we evaluated changes in BMD and TBS in
Graves' disease patients treated with anti-thyroid therapy.
2. Materials and methods2.1. Study design and participantsWe retrospectively reviewed the medical records of pre-
menopausal female and male patients with Graves' disease be-
tween March 2005 and May 2014 at Ajou University Hospital.
Diagnosis of Graves' disease was based on patient history,
physical examination, 99mTc thyroid scan and serum free
thyroxine (FT4), total triiodothyronine (T3), thyroid stimu-
lating hormone (TSH), and TSH receptor antibody (TRAb)
levels. We defined Graves' disease patients who has hyperthy-
roidism, increased levels of serum FT4, T3 and decreased levels
of TSH, with elevated diffuse radioiodine uptake in thyroid scan
or elevated TSH receptor antibody [13]. Patients who received
more than two BMDmeasurements during the treatment period
were selected. Patients with a history of spine fracture, severe
hepatic and/or renal disease, alcoholism, hyperparathyroidism
or other major medical conditions were excluded. No patients
had taken calcium, vitamin D supplements or other drugs that
can affect bone metabolism.2.2. MeasurementTable 1
Characteristics of 30 Graves' disease patients (20.7 ± 8.5-month follow-up).
Initial Follow up p
Age, years 36.0 (29.5e44) 37.5 (30.8e46.0) <0.001
Height, cm 165.35 (159.95e171.98) 165.60 (160.65e171.63) 0.390
Weight, kg 59.5 (52.7e68.0) 62.3 (56.18e69.8) <0.001
BMI, kg/m2 21.4 (19.9e24.1) 22.2 (20.8e25.6) <0.001
T3, ng/dL 220 (139e381) 102 (89e111) <0.001
Free T4, ng/dL 2.55 (2.07e3.78) 1.28 (1.23e1.39) <0.001
TSH, mIU/L 0.015 (0.01e0.04) 0.89 (0.35e1.55) <0.001
TRAb, IU/L 17.0 (5.0e40.3) 5.0 (5.0e6.0) 0.001
Z-score 0.7 (1.25e0.20) 0.3 (0.95e0.05) 0.042
Data are expressed as median (Interquartile ranges; 25 percentile-75
percentile).
Reference values: T3: 65e150 ng/dL; Free T4: 0.89e1.76 ng/dL; TSH:
0.55e4.78 mIU/L; TRAb: <15% (gray zone 9e14%).
BMI, body mass index; TSH, Thyroid-stimulating hormone; TRAb, Thyroid-
stimulating hormone receptor antibody.Subject height and weight were measured at each BMD
examination. Body mass index (BMI) was calculated as weight
in kg divided by the square of height in meters. Basal serum
FT4, T3 and TSH levels were assessed with an Advia Centaur
Immunodiagnostic system (Siemens Healthcare Diagnostics,
Tarrytown, NY, USA). The reference ranges were
0.89e1.76 ng/dL for fT4, 76e190 ng/dL for T3 and
0.55e4.78 mIU/L for TSH. TRAb levels were measured by
radio-receptor assay (TSH Rezak; Medipan Diagnostica, Ger-
many; normal values <15%). BMD was measured with dual X-
ray absorptiometry (GE Lunar®) in the lumbar spine (LS) and
femur. For lumbar spine BMD, when the specific vertebraewere
not suitable for analysis due to degenerative changes or any
other reasons, BMD was calculated excluding the affected
vertebrae. Our center's coefficient of variation for BMD is
0.937% in the LS. All DXA scans were analyzed, and TBS was
calculated using TBS insight® software (version 2.1) with DXA
images on the same vertebrae as in the BMD measurements.
The coefficient of variation for TBS measurement is 1.408% in
the LS at our center. This study was approved by Institutional
Review Board of Ajou University Hospital (IRB No. AJIRB-
MED-MDB-14-247). And we retrospectively reviewed patient
medical records, thus Institutional Review Board agreed waiver
of requirement of informed consent for this study.2.3. Statistical analysisWilcoxon signed rank test was used to compare changing
patterns of parameters with treatment, and a subgroup analysis
was done with newly diagnosed patients. All results are
expressed as medians and interquartile ranges (IQR). A p-
value <0.05 was considered statistically significant. All cal-
culations were performed using SPSS 18.0 software (SPSS,
Inc. Chicago, IL, USA).
3. Results
A total of 17 (56.6%) males and 13 (43.3%) premenopausal
females with Graves' disease with a mean age 35.3 ± 9.9 years
were included. The mean follow-up period was 20.7 ± 8.5
months. In terms of thyroid function tests, free T4 and TRAb
levels decreased at follow-up [2.55 ng/dL (IQR 2.07e3.78) to
1.28 ng/dL (IQR 1.23e1.39), 17.0 IU/L (IQR 5.0e40.3) to 5.0
(5.0e6.0) IU/L, respectively; p < 0.001], while TSH level
increased at follow-up [0.015 mIU/L (IQR 0.01e0.04) to
0.89 mIU/L (IQR 0.35e1.55), p < 0.001; Table 1]. Median
BMD (LS) values were 1.118 g/cm2 (IQR 1.000e1.119) at
baseline and significantly increased at follow-up without any
specific osteoporosis treatment as thyroid function tests
improved [1.118 g/cm2 (IQR 1.000e1.119) to 1.167 g/cm2
(IQR 1.050e1.219), p ¼ 0.001; Fig. 1]. Z-score increased
along with BMD [e0.7 (IQR e1.25e0.2) to e0.3 (IQR
e0.95e0.05)]. TBS also increased at follow-up [1.377 (IQR
1.299e1.422) to 1.390 (IQR 1.327e1.430), p ¼ 0.038; Fig. 1].
These findings indicate that median bone density improved
after anti-thyroid treatment in Graves' disease patient, as seen
in previous studies.
Among the 30 patients, 19 were newly diagnosed with
Graves' disease. The median follow-up period for BMD was
16 months (IQR 12-29) in newly diagnosed patients. Changes
in FT4, TSH and TRAb level at follow-up in newly diagnosed
patients were similar to those observed in all 30 patients. BMD
improved from 1.11 g/cm2 (IQR 0.97e1.19) to 1.15 g/cm2
(IQR 1.06e1.23) after anti-thyroid therapy in the newly
diagnosed group ( p ¼ 0.001). TBS also improved after
Fig. 1. Changes in bone mineral density (BMD) and trabecular bone score (TBS) in lumbar spine in premenopausal and male Graves' disease patients after anti-
thyroid treatment (n ¼ 30).
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respectively, p ¼ 0.038; Table 2]. For the 11 patients who were
on anti-thyroid treatment when they took the first BMD
measurements, there were no significant differences between
initial and follow-up BMD and TBS ( p ¼ 0.182 and
p ¼ 0.347, respectively).
4. Discussion
The aim of this study was to evaluate changes in bone
density represented by BMD and bone quality using TBS in
Graves' disease patients after anti-thyroid therapy.
Hyperthyroidism is a hypermetabolic state with elevated
levels of thyroid hormone. Graves' disease is one usual causeTable 2
Characteristics of newly diagnosed 19 and already diagnosed 11 Graves' disease p
Newly diagnosed patients (n ¼ 19)
Initial Follow up
Age, years 35 (30e43) 36 (31e45)
Height, cm 163.0 (159.0e141.6) 163.0 (158.8e171.3)
Weight, kg 55.2 (52.2e62.4) 60.5 (52.7e66.4)
BMI, kg/m2 20.8 (19.4e23.4) 21.9 (20.4e25.4)
T3, ng/dl 239 (208e407) 103 (91e110)
Free T4, ng/dL 3.44 (2.52e4.10) 1.28 (1.23e1.37)
TSH, mIU/L 0.01 (0.01e0.04) 0.63 (0.14e1.40)
TRAb, IU/L 27 (11e57) 5 (5e5)
BMD (LS), g/cm2 1.11 (0.97e1.19) 1.15 (1.06e1.23)
TBS (LS) 1.41 (1.38e1.46) 1.43 (1.37e1.49)
Z-score (LS) 0.8 (1.20e0.30) 0.2 (0.90e0.40)
Treatment period, month 16 (12e29)
Data are expressed as median (Interquartile ranges; 25 percentile-75 percentile).
Reference values: T3: 65e150 ng/dL; Free T4: 0.89e1.76 ng/dL; TSH: 0.55e4.7
BMI, body mass index; TSH, Thyroid-stimulating hormone; TRAb, Thyroid-stimuof hyperthyroidism and a known risk factor of osteoporosis.
The mechanism of osteoporosis in Graves' disease is mainly
acceleration of bone turnover rate. Osteoclastic bone resorp-
tion rate is faster than osteoblastic remineralization, reducing
bone mass. The bone remodeling cycle is shortened by almost
half, and about 10% of mineralized bone mass is reduced in
every cycle in severe Graves' disease [14].
Several studies have also demonstrated other associated
mechanisms. Thyroid hormone plays important roles in skel-
etal growth and bone mass maintenance. T3in particular is
associated with bone development and growth [15]. The thy-
roid gland mainly secretes pro-hormone T4 in response to
TSH stimulation [16]. Most circulating T3 is converted from
T4 by type 2 iodothyronine deiodinase enzymes (D2) [17].atients.
Previously diagnosed patients (n ¼ 11)
p Initial Follow up p
<0.001 39 (28e45) 41 (30e50) 0.003
0.39 167.1 (163.2e173.5) 167.5 (163.3e173.8) 0.622
<0.001 67.0 (60.9e72.9) 68.4 (60.4e73.0) 0.247
<0.001 23.6 (21.3e25.8) 23.8 (21.9e26.4) 0.248
<0.001 132 (124e161) 99 (81e127) 0.012
<0.001 2.10 (1.67e2.29) 1.28 (1.21e1.43) 0.003
<0.001 0.02 (0.01e0.04) 1.08 (0.38e2.17) 0.003
<0.001 10 (5e20) 5 (5e16) 0.263
0.001 1.19 (1.01e1.21) 1.18 (1.04e1.22) 0.182
0.038 1.31 (1.28e1.39) 1.35 (1.28e1.37) 0.347
0.010 0.5 (1.38e0.08) 0.55 (1.59e0.10) 0.929
36 (20e40) 52 (47e73)
8 mIU/L; TRAb: <15%(gray zone 9e14%).
lating hormone receptor antibody; LS, Lumbar spine.
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receptors (TRs), a nuclear receptor superfamily [15,16].
Because T3 binds to TRs with a 100-fold higher affinity than
T4, T3 enters the cell nucleus to take the TR ligand binding
site [18]. T3 receptors (TRs) a and b, encoded by the genes
THRA and THRB, respectively, are expressed in chon-
drocytes, osteoblasts and osteoclasts [16,17,19]. TRa is more
dominant than TRb, with almost 10-fold higher ranges in bone
[20]. T3 is also associated with skeletal growth control by
indian hedgehog (Ihh) and local feedback mechanism of
PTHrP, which inhibits differentiation and growth of prolifer-
ating chondrocytes [21e23]. TSH is a known independent
factor associated with bone resorption that, when bound to the
TSH receptor in osteoblast and osteoclast precursors, inhibits
bone turnover rate [24]. Other skeletal responses to thyroid
hormones are less well understood, including growth hormone,
insulin-like growth factor1 and Wnt-b catenin pathways
[19,20,25e27].
Studies about the reversibility of bone loss after thyroid
function normalization with treatment have yielded variable
results in hyperthyroid patients. Krolner et al. found a 5%
increase in bone mineral contents after a two-year treatment
period in thyrotoxicosis patients [28]. Rosen et al. also re-
ported an 11% lumbar bone density increase after thyroid
function normalization [29]. In contrast, Toh et al. reported
insignificant recovery of bone mineral contents (BMC) after
euthyroid status in hyperthyroid patients in a longitudinal
prospective study [30]. Overall, our observations are consis-
tent with the majority of previous studies, which found that
bone mineral density recovered some, but not completely, after
hyperthyroid treatment [1,2,28,29,31].
Bone strength, which is closely related to bone fragility,
depends not only on bone quantity, as represented by BMD,
but also bone quality. Few studies have been done to measure
bone quality, which is assessed by many factors including
bone turnover rate, bone microarchitecture and micro-
damage accumulation. Acotto et al. reported poor bone ar-
chitecture and decreased elasticity as measured by quanti-
tative ultrasound in hyperthyroidism patients [32], but did
not describe changes in these parameters after anti-thyroid
treatment.
To our knowledge, this is the first report about changes in
bone quality as represented by TBS in Graves' disease patients
after anti-thyroid treatment.
Our study has some limitations. We did not include bone
turnover markers, such as serum alkaline phosphatase, serum
osteocalcin, urine N-telopeptide and urine C-telopeptide.
Because of the retrospective design, these data could not be
fully collected.
In conclusion, both bone density and quality improved after
anti-thyroid treatment in premenopausal female and male
patients with Graves' disease.
Conflicts of interest
Authors report no conflicts of interest.Acknowledgment
Authors are grateful to technologist ByungJoo Lee for his
assistance with the analyses of trabecular bone score.
References
[1] Jodar E, Martinez-Diaz-Guerra G, Azriel S, Hawkins F. Bone mineral
density in male patients with L-thyroxine suppressive therapy and Graves
disease. Calcif Tissue Int 2001;69:84e7.
[2] Lucidarme N, Ruiz JC, Czernichow P, Leger J. Reduced bone mineral
density at diagnosis and bone mineral recovery during treatment in
children with Graves' disease. J Pediatr 2000;137:56e62.
[3] Vestergaard P, Mosekilde L. Hyperthyroidism, bone mineral, and fracture
riskea meta-analysis. Thyroid 2003;13:585e93.
[4] Karga H, Papapetrou PD, Korakovouni A, Papandroulaki F, Polymeris A,
Pampouras G. Bone mineral density in hyperthyroidism. Clin Endocrinol
(Oxf) 2004;61:466e72.
[5] Langdahl BL, Loft AG, Eriksen EF, Mosekilde L, Charles P. Bone mass,
bone turnover, body composition, and calcium homeostasis in former
hyperthyroid patients treated by combined medical therapy. Thyroid
1996;6:161e8.
[6] Seeman E, Delmas PD. Bone qualityethe material and structural basis of
bone strength and fragility. N Engl J Med 2006;354:2250e61.
[7] Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg MA.
Correlations between trabecular bone score, measured using ante-
roposterior dual-energy X-ray absorptiometry acquisition, and 3-dimen-
sional parameters of bone microarchitecture: an experimental study on
human cadaver vertebrae. J Clin Densitom 2011;14:302e12.
[8] Bousson V, Bergot C, Sutter B, Levitz P, Cortet B. Scientific Committee
of the Groupe de Recherche et d'Information sur les O. Trabecular bone
score (TBS): available knowledge, clinical relevance, and future pros-
pects. Osteoporos Int 2012;23:1489e501.
[9] Pothuaud L, Barthe N, Krieg MA, Mehsen N, Carceller P, Hans D.
Evaluation of the potential use of trabecular bone score to complement
bone mineral density in the diagnosis of osteoporosis: a preliminary spine
BMD-matched, case-control study. J Clin Densitom 2009;12:170e6.
[10] Boutroy S, Hans D, Sornay-Rendu E, Vilayphiou N, Winzenrieth R,
Chapurlat R. Trabecular bone score improves fracture risk prediction in
non-osteoporotic women: the OFELY study. Osteoporos Int 2013;24:
77e85.
[11] Leslie WD, Aubry-Rozier B, Lamy O, Hans D. Manitoba bone density P.
TBS (trabecular bone score) and diabetes-related fracture risk. J Clin
Endocrinol Metab 2013;98:602e9.
[12] Romagnoli E, Cipriani C, Nofroni I, Castro C, Angelozzi M,
Scarpiello A, et al. “Trabecular Bone Score” (TBS): an indirect measure
of bone micro-architecture in postmenopausal patients with primary
hyperparathyroidism. Bone 2013;53:154e9.
[13] Gregory A. Graves' disease. N Engl J Med 2008;358:2594e605.
[14] Eriksen EF, Mosekilde L, Melsen F. Trabecular bone remodeling and
bone balance in hyperthyroidism. Bone 1985;6:421e8.
[15] Bassett JH, Williams GR. The molecular actions of thyroid hormone in
bone. Trends Endocrinol Metab 2003;14:356e64.
[16] Gogakos AI, Duncan Bassett JH, Williams GR. Thyroid and bone. Arch
Biochem Biophys 2010;503:129e36.
[17] Murphy E, Williams GR. The thyroid and the skeleton. Clin Endocrinol
(Oxf) 2004;61:285e98.
[18] Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochem-
istry, cellular and molecular biology, and physiological roles of the
iodothyronine selenodeiodinases. Endocr Rev 2002;23:38e89.
[19] Waung JA, Bassett JH, Williams GR. Thyroid hormone metabolism in
skeletal development and adult bone maintenance. Trends Endocrinol
Metab 2012;23:155e62.
[20] Stevens DA, Hasserjian RP, Robson H, Siebler T, Shalet SM,
Williams GR. Thyroid hormones regulate hypertrophic chondrocyte
differentiation and expression of parathyroid hormone-related peptide
179S.Y. Ock et al. / Osteoporosis and Sarcopenia 2 (2016) 175e179and its receptor during endochondral bone formation. J Bone Min Res
2000;15:2431e42.
[21] Ballock RT, Reddi AH. Thyroxine is the serum factor that regulates
morphogenesis of columnar cartilage from isolated chondrocytes in
chemically defined medium. J Cell Biol 1994;126:1311e8.
[22] Robson H, Siebler T, Stevens DA, Shalet SM, Williams GR. Thyroid
hormone acts directly on growth plate chondrocytes to promote hyper-
trophic differentiation and inhibit clonal expansion and cell proliferation.
Endocrinology 2000;141:3887e97.
[23] Dentice M, Bandyopadhyay A, Gereben B, Callebaut I,
Christoffolete MA, Kim BW, et al. The Hedgehog-inducible ubiquitin
ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP
secretion in the developing growth plate. Nat Cell Biol 2005;7:698e705.
[24] Novack DV. TSH, the bone suppressing hormone. Cell 2003;115:
129e30.
[25] O'Shea PJ, Bassett JH, Sriskantharajah S, Ying H, Cheng SY,
Williams GR. Contrasting skeletal phenotypes in mice with an identical
mutation targeted to thyroid hormone receptor alpha1 or beta. Mol
Endocrinol 2005;19:3045e59.
[26] Barnard JC, Williams AJ, Rabier B, Chassande O, Samarut J,
Cheng SY, et al. Thyroid hormones regulate fibroblast growth factorreceptor signaling during chondrogenesis. Endocrinology 2005;146:
5568e80.
[27] Wang L, Shao YY, Ballock RT. Thyroid hormone interacts with the Wnt/
beta-catenin signaling pathway in the terminal differentiation of growth
plate chondrocytes. J Bone Min Res 2007;22:1988e95.
[28] Krolner B, Jorgensen JV, Nielsen SP. Spinal bone mineral content in
myxoedema and thyrotoxicosis. Effects of thyroid hormone(s) and anti-
thyroid treatment. Clin Endocrinol 1983;18:439e46.
[29] Rosen CJ, Adler RA. Longitudinal changes in lumbar bone density
among thyrotoxic patients after attainment of euthyroidism. J Clin
Endocrinol metab 1992;75:1531e4.
[30] Toh SH, Claunch BC, Brown PH. Effect of hyperthyroidism and its
treatment on bone mineral content. Arch Intern Med 1985;145:883e6.
[31] Nagasaka S, Sugimoto H, Nakamura T, Kusaka I, Fujisawa G,
Sakuma N, et al. Antithyroid therapy improves bony manifestations and
bone metabolic markers in patients with Graves' thyrotoxicosis. Clin
Endocrinol 1997;47:215e21.
[32] Gomez Acotto C, Schott AM, Hans D, Niepomniszcze H, Mautalen CA,
Meunier PJ. Hyperthyroidism influences ultrasound bone measurement
on the Os calcis. Osteoporos Int 1998;8:455e9.
